Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12579952 | 0.86 | HTR2C (0.71) | HTR2CHTR6MTNR1AMTNR1BHTR2A | |
| SCHEMBL905797 | 0.85 | HTR2C (0.77) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| Hydrochloric Acid SCHEMBL5231123 | 0.84 | HTR2C (0.75) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| SCHEMBL5237243 | 0.83 | HTR2C (0.77) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| Hydrochloric Acid SCHEMBL5240019 | 0.82 | HTR2C (0.75) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| SCHEMBL905928 | 0.81 | HTR6 (0.66) | HTR2CHTR6MTNR1AMTNR1BHTR1D | |
| SCHEMBL5234288 | 0.79 | HTR2C (0.71) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| SCHEMBL905848 | 0.79 | HTR2C (0.78) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| Hydrochloric Acid SCHEMBL5233162 | 0.78 | HTR2C (0.77) | HTR2CHTR6MTNR1AMTNR1BACHE | |
| SCHEMBL5234060 | 0.77 | HTR2C (0.74) | HTR2CHTR6MTNR1AMTNR1BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR6 21/4885MTNR1A 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.